A clinical-stage biopharmaceutical business with a focus on cardiovascular disease.

Amarin completes patient randomization in AMR101 Stage 3 trial in sufferers with high triglyceride levels Amarin Corporation plc , a clinical-stage biopharmaceutical business with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. THE BUSINESS indicated that it anticipates reporting top-line results from this trial in Q2 2011 http://www.montfordpharmacy.com . The ANCHOR trial can be a multi-center, placebo-managed, randomized, double-blind, 12-week pivotal research to evaluate the efficacy and basic safety of 2 grams and 4 grams of AMR101 in sufferers with high triglyceride amounts from 200 mg/dL to less than 500 mg/dL who are also on statin therapy.

Ambulatory syringe pump training: an interview with Ruth Goodwin RGN, BSc Clinical Education Manager for CME Medical By April Cashin-Garbutt Interview conducted, BA Hons What exactly are ambulatory syringe pumps and what are they used for? Ambulatory pumps allow individuals to continue receiving treatment or therapy from a hospital, thereby leading a normal life during treatment. Because of the size and design of these pumps, individuals can carry them around in a carry pouch. Therapies that can be administered by ambulatory pumps, for instance: analgesia, antiviral or antibiotic infusions, chemotherapy and hormone delivery. We produce electronic and paper forms of user instructions for starting, monitoring and troubleshooting infusions with numerous versions based on the mode of procedure of the pump.